Simulations Plus, Inc.
SLPSimulations Plus, Inc. (SLP) is a software company specializing in developing pharmacometric and pharmacokinetic modeling and simulation tools for the pharmaceutical, biotech, and health care industries. Founded in 1996, the company provides solutions that aid in drug discovery, development, and regulatory approval processes, with a focus on optimizing clinical trial design and understanding drug behavior. Its flagship products include GastroPlus, ABLAs, and other modeling platforms used by scientists and researchers worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 5, 2024 | $0.06 | 2024-07-29 | 2024-07-29 |
| May 6, 2024 | $0.06 | 2024-04-26 | 2024-04-29 |
| February 5, 2024 | $0.06 | 2024-01-26 | 2024-01-29 |
| November 6, 2023 | $0.06 | 2023-10-27 | 2023-10-30 |
| August 7, 2023 | $0.06 | 2023-07-28 | 2023-07-31 |
Dividends Summary
- Simulations Plus, Inc. has issued 51 dividend payments over the past 12 years
- The most recent dividend was paid 490 days ago, on August 5, 2024
- The highest dividend payed out to investors during this period was $0.14 per share
- The average dividend paid during this period was $0.06 per share.
Company News
Simulations Plus reported mixed Q4 results with a 6% revenue decline, but provided optimistic fiscal 2026 guidance projecting 0-4% revenue growth and potential AI-driven solutions, leading to a 21.6% stock price increase.
Simulations Plus reported a significant quarterly loss of $67.3 million, missed sales estimates, and initiated a restructuring, causing its stock price to drop 25.76%.
The FDA announced a major shift towards adopting human-relevant and technologically advanced testing methods, including AI-based simulations and lab-grown organoids, to evaluate monoclonal antibody therapies and other drugs, reducing the reliance on traditional animal testing.
JMP Securities initiated coverage on Simulations Plus stock, assigning a Market Perform rating. The company is recognized for its substantial experience in Model Informed Drug Development (MIDD) and its balanced approach of robust organic growth and strategic acquisitions.
Simulations Plus, Inc. reported third-quarter fiscal 2024 adjusted earnings that declined 9.5% year-over-year but topped the Zacks Consensus Estimate. The company's top line increased 14% year over year, primarily due to higher software revenues. Simulations Plus has also opted to discontinue the quarterly cash dividend and redirect these funds t...
